ECOG-ACRIN EA7222 Trial Overview

The ECOG-ACRIN Cancer Research Group is leading a Phase 3, randomized clinical trial, EA7222 (NCT06422806), to evaluate the efficacy of a combination therapy in patients with advanced or unresectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS). Dr. Seth Pollack from Northwestern University's Robert H. Lurie Comprehensive Cancer Center serves as the principal investigator, and Dr. Richard F. Reidel from Duke University acts as the Community Co-Chair, expanding participation from regional institutions. The trial aims to enroll approximately 180 patients.

Trial Design and Crossover Strategy

Arm A involves administering doxorubicin in combination with pembrolizumab (Keytruda) every three weeks for six cycles, followed by maintenance pembrolizumab for up to two years. Arm B consists of doxorubicin alone administered for six cycles, followed by observation. A key aspect of the trial design is the ability for patients in Arm B to cross over to receive single-agent pembrolizumab upon disease progression. The primary endpoint is progression-free survival (PFS), and overall survival (OS) comparison after crossover is a key secondary endpoint. Only patients who have not previously received anthracycline-based chemotherapy or anti-PD-1/PD-L1/CTLA-4 therapy are eligible.

Scientific Rationale Based on SARC032 Data

The SU2C-SARC032 trial results, which served as the scientific basis for this trial, were published in The Lancet in November 2024. In a study of 127 patients with Stage 3 UPS, the neoadjuvant radiation plus pembrolizumab combination arm demonstrated a 2-year disease-free survival (DFS) rate of 67%, compared to 52% in the radiation plus surgery alone arm, representing a 15-percentage-point improvement (HR 0.61, 90% CI 0.39-0.96, p=0.035, median follow-up of 43.1 months). The primary driver was a reduction in distant metastases, providing strong clinical evidence that pembrolizumab can effectively activate immune responses within the UPS tumor microenvironment. However, the increase in Grade 3 or higher adverse events to 56% (compared to 31% in the control group) highlights the importance of long-term safety monitoring.

Market Landscape and Competitive Dynamics

The current standard of care for advanced soft tissue sarcoma is doxorubicin-based therapy. Subsequent lines of therapy include trabectedin (Yondelis, Janssen/PharmaMar), pazopanib (Votrient, Novartis), and eribulin (Halaven, Eisai). The soft tissue sarcoma therapeutics market is projected to grow from approximately $4.1 billion in 2025 to $8.3 billion in 2033, with a compound annual growth rate (CAGR) of 9.6%. Merck's Keytruda generated $31.7 billion in revenue in 2025 (49% of Merck's total revenue) and has over 40 FDA-approved indications, but it has not yet received FDA approval for sarcoma indications.

Strategic Significance of a Public Institution-Led Trial

EA7222 is a trial led by the ECOG-ACRIN cooperative research group, which is affiliated with the U.S. National Cancer Institute (NCI). This structure minimizes commercial bias compared to trials solely sponsored by pharmaceutical companies. Positive results from a Phase 3 trial led by a public institution are likely to increase regulatory confidence during FDA approval reviews and provide strong evidence for insurance coverage decisions. Given the small patient population characteristic of rare sarcomas, public research infrastructure is pioneering the development of therapies for indications that pharmaceutical companies may be reluctant to invest in due to profitability concerns.